Trial Profile
Trimetazidine in patients with valvular heart disease who have undergone valve replacement
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Oct 2013
Price :
$35
*
At a glance
- Drugs Trimetazidine (Primary)
- Indications Heart failure; Left ventricular dysfunction; Valvular heart disorders
- Focus Therapeutic Use
- 01 Oct 2013 New trial record
- 04 Sep 2013 Efficacy and tolerability results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
- 04 Sep 2013 Quality-of-life results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.